Royal Bank of Canada
IMDX

Royal Bank of Canada’s Insight Molecular Diagnostics IMDX Stock Holding History

Royal Bank of Canada’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-80
Closed – – 7391
2024
Q1 		$0 Sell
80
-821
-91% -$2.54K ﹤0.01% 7418
2023
Q4 		$2K Sell
901
-118
-12% -$363 ﹤0.01% 6826
2023
Q3 		$3K Buy
1,019
+852
+510% +$3.17K ﹤0.01% 6724
2023
Q2 		$1K Buy
167
+138
+476% +$695 ﹤0.01% 7049
2023
Q1 		$0 Sell
29
-3
-9% -$22 ﹤0.01% 7348
2022
Q4 		$0 Sell
32
-185
-85% -$2.04K ﹤0.01% 7570
2022
Q3 		$3K Buy
217
+187
+623% +$3.24K ﹤0.01% 6909
2022
Q2 		$1K Sell
30
-202
-87% -$4.59K ﹤0.01% 7170
2022
Q1 		$7K Sell
232
-1,479
-86% -$47.3K ﹤0.01% 7115
2021
Q4 		$74K Buy
1,711
+1,282
+299% +$73.7K ﹤0.01% 6141
2021
Q3 		$30K Buy
429
+121
+39% +$11.1K ﹤0.01% 6468
2021
Q2 		$35K Sell
308
-44
-13% -$4.3K ﹤0.01% 6265
2021
Q1 		$37K Sell
352
-124
-26% -$11.8K ﹤0.01% 6072
2020
Q4 		$23K Buy
476
+204
+75% +$7.48K ﹤0.01% 5999
2020
Q3 		$8K Buy
272
+3
+1% +$86 ﹤0.01% 6006
2020
Q2 		$10K Sell
269
-102
-27% -$5.27K ﹤0.01% 5833
2020
Q1 		$18K Buy
371
+104
+39% +$5.1K ﹤0.01% 5590
2019
Q4 		$12K Sell
267
-7
-3% -$253 ﹤0.01% 6072
2019
Q3 		$12K Sell
274
-8
-3% -$314 ﹤0.01% 5710
2019
Q2 		$14K Buy
282
+15
+6% +$1.25K ﹤0.01% 5895
2019
Q1 		$21K Buy
267
+249
+1,383% +$16.1K ﹤0.01% 5629
2018
Q4 		$0 Sell
18
-251
-93% -$9.03K ﹤0.01% 7004
2018
Q3 		$13K Hold
269
– – ﹤0.01% 5882
2018
Q2 		$14K Buy
269
+249
+1,245% +$12.3K ﹤0.01% 5707
2018
Q1 		$1K Hold
20
– – ﹤0.01% 6216
2017
Q4 		$2K Sell
20
-14
-41% -$1.58K ﹤0.01% 6286
2017
Q3 		$6K Buy
34
+12
+55% +$1.26K ﹤0.01% 6396
2017
Q2 		$2K Sell
22
-6
-21% -$683 ﹤0.01% 6280
2017
Q1 		$3K Buy
28
+16
+133% +$1.85K ﹤0.01% 6356
2016
Q4 		$2K Sell
12
-5
-29% -$551 ﹤0.01% 6482
2016
Q3 		$2K Sell
17
-28
-62% -$2.26K ﹤0.01% 6184
2016
Q2 		$3K Buy
45
+26
+137% +$2.43K ﹤0.01% 6068
2016
Q1 		$2K Buy
+19
New +$1.68K ﹤0.01% 6132

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada's IMDX Position: Q2 2024 in Review

Royal Bank of Canada sold out of Insight Molecular Diagnostics (IMDX) in Q2 2024, closing a stake of 80 shares.

Royal Bank of Canada first reported a position in IMDX in Q1 2016 and held it in 33 quarters. The position peaked at $74K in Q4 2021. 23 funds tracked by Wall St. Rank hold IMDX as of Q2 2024.

  • Royal Bank of Canada reported no remaining Insight Molecular Diagnostics position as of Q2 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 80 Insight Molecular Diagnostics shares in Q2 2024.
  • Royal Bank of Canada first reported a position in Insight Molecular Diagnostics in Q1 2016 and held it in 33 quarters.
  • Royal Bank of Canada's Insight Molecular Diagnostics position peaked at $74K in Q4 2021.
  • 23 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2024.

Based on Royal Bank of Canada's 13F filing for Q2 2024, filed 14 Aug 2024.